Related Experiment Video

Updated: Aug 6, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment of hepatitis C infection

Rise Stribling1, Norman Sussman, John M Vierling

  • 1Department of Medicine, Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA.

Gastroenterology Clinics of North America
|August 2, 2006
PubMed

Insights

Hepatitis C (HCV) infection causes chronic liver disease and is a leading cause for liver transplants. While curable with antiviral therapy, few receive treatment, highlighting a critical public health gap.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection is a major global cause of chronic liver disease, leading to cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
  • HCV-induced cirrhosis is a primary indication for liver transplantation.
  • Despite effective antiviral therapies, a significant number of infected individuals remain untreated.

Purpose of the Study:

  • To review current treatment standards for Hepatitis C virus (HCV) infection.
  • To discuss treatment recommendations for various patient populations.
  • To explore emerging therapeutics for difficult-to-treat and non-responsive cases.

Main Methods:

  • Review of current standard therapy: PEG-IFNalpha and ribavirin.
  • Analysis of sustained virologic response (SVR) rates across different HCV genotypes.
  • Examination of treatment recommendations for conventional and special patient groups.
  • Assessment of newer therapeutics in clinical trials.

Main Results:

  • The standard therapy (PEG-IFNalpha and ribavirin) achieves SVR rates of 42%-56% for genotype 1 and 75%-84% for genotypes 2 and 3.
  • Genotypes 4, 5, and 6 also show responsiveness to combination therapy.
  • Treatment guidelines for diverse patient populations were detailed.

Conclusions:

  • Hepatitis C virus (HCV) infection, though curable, is under-treated globally.
  • Current therapies offer significant SVR rates, with ongoing research promising better outcomes for challenging cases.
  • Further development of novel therapeutics is crucial to improve treatment accessibility and efficacy for all HCV patients.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...